Christenbury JG, et al. - Researchers assessed the size and location of macular atrophy in eyes with Type-1 neovascularization (NV) and age-related macular degeneration receiving chronic intravitreal anti-vascular endothelial growth factor therapy. As per data, macular atrophy tends to develop predominantly eccentric to the PED and the neovascular flow imaged on OCT angiography with long-term anti–vascular endothelial growth factor therapy for eyes with Type-1 NV secondary to age-related macular degeneration. Findings suggested evaluation of Type-1 NV into a multilayered PED that may confer a protective effect on the overlying retinal pigment epithelium and outer retina with chronic vascular endothelial growth factor suppression.